Dogwood Therapeutics, INC

Dogwood Therapeutics, Inc. announced the outcomes of its annual stockholder meeting, including the approval of amendments to its Certificate of Incorporation and the election of directors.

Dogwood Therapeutics announced Q1 2026 results, highlighting progress in Halneuron and SP16 clinical trials, an FDA IND acceptance, and a new global development partnership for legacy assets.

Dogwood Therapeutics reports significant progress in its non-opioid pain and neuropathy pipeline, including patient recruitment, a $12.5 million capital raise, and new IND filings.

Dogwood Therapeutics announced its Q4 and full year 2025 financial results, highlighting progress in its Halneuron Phase 2b trial and recent financing.

Dogwood Therapeutics, Inc. announced that its shareholders approved the potential exercise of an unregistered common stock warrant for up to 4,386,037 shares and the issuance of common stock.

Dogwood Therapeutics provides a corporate update, highlighting 2025 progress in its non-opioid pain and neuropathy pipeline and outlining key 2026 milestones.

Dogwood Therapeutics reports increased R&D and G&A expenses in Q1 2026, with cash reserves projected to fund operations into Q4 2026, necessitating future financing.

Dogwood Therapeutics, a pre-revenue biopharmaceutical company, reported significant net losses for Q3 2025 and indicated a need for additional financing to fund operations beyond Q1 2026.

Dogwood Therapeutics, a pre-revenue biopharmaceutical company, reported a significant increase in net loss and operating expenses, raising substantial doubt about its ability to continue as a going concern.

Dogwood Therapeutics announces its Q1 2025 financial results, highlighting advancements in its Halneuron clinical trial and addressing Nasdaq compliance.

Dogwood Therapeutics, formerly Virios Therapeutics, announced its Q3 2024 financial results, the acquisition of Pharmagesic, and a $16.5 million loan, while also highlighting its pipeline progress.

Virios Therapeutics reported its financial results for the second quarter of 2024, highlighting ongoing clinical development and financial challenges.

Dogwood Therapeutics reports significant R&D investment and clinical trial progress for its pain and neuropathy pipeline, alongside substantial net losses and ongoing capital needs.

Dogwood Therapeutics' 2024 10-K filing highlights its focus on developing Halneuron for chemotherapy-induced neuropathic pain and antiviral therapies for fibromyalgia and Long-COVID, while addressing concerns about its ability to continue as a going concern.

Virios Therapeutics files an amendment to its annual report to include a missing sentence in the auditor's opinion and reaffirms the accuracy of its financial statements and internal controls.

Virios Therapeutics' 2023 10-K filing highlights ongoing clinical development of IMC-1 and IMC-2, along with financial challenges and the need for additional capital.

Dogwood Therapeutics, Inc. reports a Form 4 filing detailing stock option transactions by Director Abel De La Rosa.

Dogwood Therapeutics, Inc. director Thomas John C acquired stock options granting the right to buy 16,800 shares.

Richard James Whitley, a Director at Dogwood Therapeutics, Inc., acquired stock options for 16,800 shares.

Director David R. Keefer of Dogwood Therapeutics, Inc. reported the acquisition of 16,800 shares of common stock via stock options.

Dogwood Therapeutics' SVP of Operations, Ralph Grosswald, was granted 82,500 stock options with an exercise price of $2.86.

Dogwood Therapeutics' Chief Financial Officer, Angela Walsh, was granted 82,500 stock options with an exercise price of $2.86.

Dogwood Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 16, 2026, to vote on director elections, auditor ratification, and charter amendments.

Dogwood Therapeutics, Inc. calls a special meeting to approve the conversion of non-voting preferred stock into common stock, significantly diluting existing shareholders, and to expand its equity incentive plan.

Dogwood Therapeutics, Inc. provides a Q4 2025 update, detailing its deep commitment to advancing first-in-class therapeutic treatments for cancer patients suffering from neuropathy.

Dogwood Therapeutics obtained an exclusive, royalty-free global license for Serpin Pharma's SP16, a promising drug for chemotherapy-induced peripheral neuropathy, with its Phase 1b study fully funded by the National Cancer Institute.

Dogwood Therapeutics is holding its 2025 Annual Meeting of Stockholders virtually on June 18, 2025, to vote on director elections, ratification of the independent accounting firm, and approval of an amendment to the equity incentive plan.

Virios Therapeutics and Wex Pharmaceuticals have merged to create Dogwood Therapeutics, focusing on clinical development of Halneuron, IMC-1, and IMC-2, with existing Virios stockholders receiving a contingent value right (CVR).

Sealbond Limited and Conjoint Inc. convert preferred stock into common stock, significantly increasing their beneficial ownership in Dogwood Therapeutics to 73.4% and 9.6% respectively.

Dogwood Therapeutics, Inc. has converted approximately $19.9 million in outstanding debt and accrued interest owed to Conjoint Inc., a subsidiary of CK Life Sciences Int'l., (Holdings) Inc., into Series A-1 Non-Voting Convertible Preferred Stock.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 3,343,120 shares, representing 9.99% of Dogwood Therapeutics, Inc.'s common stock.

Orca Capital AG has filed an amended Schedule 13G, reporting a 3.7% beneficial ownership stake in Dogwood Therapeutics, Inc. as of March 14, 2025, following the issuer's recent registered offering.

Orca Capital AG, a German entity, has reported a 6.1% beneficial ownership stake in Dogwood Therapeutics, Inc., following the issuer's recent registered offering.